ERBB3 and cancer: Elgemtumab (LJM716) binds domains 2 and 4, and locks ErbB3 in inactive conformation, thus inhibiting both ligand-dependent and ligand-independent proliferation of various cancer cell lines, without direct interference with heregulin binding [14].